Voyager Token Integrated Into Coinify’s Global Crypto Payment Platform

 


Voyager Token Integrated Into Coinify’s Global Crypto Payment Platform

 

Integration increases VGX functionality as customers can utilize it for crypto payments

NEW YORKNov. 8, 2021 /PRNewswire/ – Voyager Digital Ltd. (“Voyager” or the “Company”) (TSX: VOYG) (OTCQX: VYGVF) (FRA: UCD2), one of the fastest-growing, publicly traded cryptocurrency platforms in the United States, today announced the integration of the Voyager token (VGX) into Coinify’s cryptocurrency payment platform, a wholly-owned Voyager subsidiary that provides merchant payment services in over 150 countries.

“The integration of VGX into Coinify’s crypto payment platform expands the functionality of the Voyager token well beyond the Voyager ecosystem,” said Steve Ehrlich, CEO and Co-founder of Voyager. “Our acquisition of Coinify earlier this year added a global crypto payments infrastructure to the Voyager ecosystem, and we will continue to implement additional ways to maximize this infrastructure to grow crypto adoption internationally.”

Coinify’s payment system allows businesses to accept cryptocurrency online and in retail stores, and is integrated through payment service providers with over 30,000 merchants globally. VGX joins over 15 other leading cryptocurrencies — including Bitcoin, Ethereum, and Cardano — that can be accepted by participating Coinify merchants. Voyager also previously announced that Usio, its payment provider, is integrating Coinify’s payment offering. Usio already has an established pipeline of merchants and PSPs ready to accept crypto as payment.

VGX supports the Voyager Loyalty Program, commonly known as VLP, which allows customers to earn rewards for activities done on the platform. The VLP rewards customers with crypto-back on trades, boosted holding rewards, and more. The program has been successful as the number of participants continues to grow.

In August 2021, Voyager acquired Coinify, accelerating Voyager’s international expansion and the Company’s payment capabilities, with plans to enable customers to make payments directly from their digital asset accounts and fast-track Voyager into the business-to-business payment space.

About Voyager Digital Ltd.
Voyager Digital Ltd. (TSX: VOYG;OTCQX: 
VYGVF; FRA: UCD2) is a fast-growing, publicly traded cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost efficiency to the marketplace. Voyager offers a secure way to trade over 60 different crypto assets using its easy-to-use mobile application, and earn rewards up to 12 percent annually on more than 30 cryptocurrencies. Through its subsidiary Coinify ApS, Voyager provides crypto payment solutions for both consumers and merchants around the globe. To learn more about the company, please visit https://www.investvoyager.com.

The TSX has not approved or disapproved of the information contained herein.

Press Contacts:

Voyager Digital, Ltd.
Michael Legg
Chief Communications Officer
(212) 547-8807
mailto:mlegg@investvoyager.com


Voyager Public Relations Team
mailto:pr@investvoyager.com

SOURCE Voyager Digital (Canada) Ltd.

PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute


PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute

 

Advances Next Phase of Versamune® Oncology Pipeline

FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced a licensing agreement with the National Cancer Institute (NCI) for intellectual property related to the NCI’s proprietary tumor-associated and immunologically active T-cell receptor gamma alternate reading frame protein (TARP).

Approximately 470,000 patients are diagnosed annually with TARP-associated cancers, including acute myeloid leukemia (AML), prostate, and breast cancer according to the National Cancer Institute. In preclinical studies performed by PDS Biotech, the administration of PDS0102, the Versamune®-TARP tumor antigen combination, led to the induction of large numbers of tumor targeted killer T-cells. It is important to note, the TARP tumor antigen alone has already been studied at the NCI in men with prostate cancer and been shown to be safe, immunogenic, and associated with slowing tumor growth rates (NCT00972309).
  
“The highly promising proof-of-concept data presented earlier this year in the advanced HPV cancer trial solidifies our confidence in the Versamune® technology to rapidly advance our pipeline into other types of debilitating cancers,” said Dr. Lauren V. Wood, PDS Biotech’s Chief Medical Officer. “We are excited about the potential of PDS0102, which leverages the Versamune® platform to improve on the results reported in humans with the NCI’s TARP antigen alone.”

The worldwide, non-exclusive license secures rights for the proprietary TARP antigen from the NCI with patent protection through 2034.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Company’s proprietary Versamune® T-cell activating technology platform. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including breast, colon, lung, prostate and ovarian cancers.   To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0102

PDS0102 combines the utility of the Versamune® platform with the proprietary T-cell receptor gamma alternate reading frame protein (TARP), a tumor antigen identified by the National Cancer Institute (NCI) which is strongly associated with acute myeloid leukemia (AML), breast and prostate cancers. Approximately 470,000 patients are projected to be diagnosed with AML, prostate, or breast cancer this year, most of which are associated with TARP.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® based products; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® based products and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: 
mailto:drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: mailto:rich@cg.capital

Salem Media Group to Present at the Upcoming Q4 Investor Summit Conference


Salem Media Group to Present at the Upcoming Q4 Investor Summit Conference

 

IRVING, Texas–(BUSINESS WIRE)– Salem Media Group, Inc. (NASDAQ: SALM) announced today it will present at the virtual Q4 Investor Summit conference at 1:00 P.M. Central Time on November 17, 2021. The presentation will be available on the investor relations portion of the company’s website www.salemmedia.com prior to the company’s presentation.

To request complimentary investor registration, please click here. To join the public Webcast, please click here.

ABOUT THE INVESTMENT SUMMIT:

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q4 Investor Summit will take place virtually, featuring 80+ companies and over 500 investors comprising of institutional investors, family offices, and high net worth investors.

ABOUT SALEM MEDIA GROUP:

Salem Media Group is America’s leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing. Each day Salem serves a loyal and dedicated audience of listeners and readers numbering in the millions nationally. With its unique programming focus, Salem provides compelling content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. Learn more about Salem Media Group, Inc. at www.salemmedia.comFacebook and Twitter.

Evan D. Masyr
Executive Vice President and Chief
Financial Officer
(805) 384-4512
evan@salemmedia.com

Source: Salem Media Group, Inc.

Released November 8, 2021

Extremely Conservative Investors May Cause Small Companies to Outperform (You Read That Right)


Image Credit: The KarenD (Flickr)

Why the Most Conservative Investors Could Help Small Stock Performance

 

Elon Musk is selling 10% of his Tesla stocks,” Amazon just missed earnings expectations, Facebook and other big tech are under an antitrust microscope, should large-cap index investors be concerned? Approximately 25% of the holdings in the S&P 500 are six large stocks (three that I have already mentioned). Perhaps, but there is a one-week-old, greater reason to believe large caps may underperform. And there is a logical reason why it hasn’t been spoken about anywhere else.

Background

Over the past 20 years, (Nov. 5, 2000 -Nov. 2021) the S&P has averaged 8.57% per year. The most recent 12 months has been the best period during these 20-years, with a 33.77% return. The worst 12-month period ended in 2008 after the S&P 500 fell 35.89%. Much of the growth has been in the largest companies, by market cap. The top five of these companies are valued at over a trillion dollars each, and the sixth, which is Facebook, is close. Together, these stocks make up one-quarter of the worth of the full index of 500 stocks. Famed hedge fund manager Michael Burry has been arguing for a couple of years that this growth has caused investors to buy S&P 500 and Nasdaq 100 funds with the idea that they are diversified, but in reality, the diversification may not be as strong as it should or could be. Burry, is famous for his “big short” against the mortgage markets that paid off in 2008. He has recently reiterated his belief that many of the other 75% of stocks in the large-cap indexes are being pulled up by index fund investors. In his mind, many of these stocks are now at undeserved valuations, and this may have created a “bubble” that could unwind quickly and severely.

Conservative investors, especially those putting money away that they will need in retirement have traditionally invested in bank CDs, US. Savings Bonds and other U.S. government guaranteed instruments. Unfortunately, beginning around the time of the 2008 financial crisis, the Federal Reserve began aggressively holding rates down. This created problems for those looking to grow wealth for retirement without risking the occasional 35.89% drop mentioned above. With interest rates hovering around 0%, and indices over the past two years rising most days by far more than 0%, a good part of retirement money that never would have been in stocks moved into the riskier index funds. Over the past 20 years, for those that held, good times and bad, they earned on average 8.57% per year. 

Risk-Free 7.12%

The most boring, and arguably safest investment vehicles are U.S. Government Savings Bonds. Maybe your grandparents gave you one when you graduated high school or on some other big occasion. Believe it or not, it was once fashionable to use payroll deductions to buy these bonds as a method to invest toward some future need. When inflation dropped, the savings bond rates that are pegged to inflation also fell. They fell so far that even a low-paying money market account seemed to make better financial sense. This has changed, and some of the more conservative money may begin to find its way out of the perceived more conservative large-cap investments and lent to Uncle Sam. 

The bonds (Series I) are 30 years to maturity, but if investors can cash out after five years without penalty, prior to five years there is a charge of the most recent three-month accrual of interest. 

On November 1st, the rates on U.S. Savings bonds

Source: U.S. Treasury Direct Nov. 1, 2021 Release

For investors that target earning of 4% or more, without issuer risk, they now have the ability to earn that and probably much more. From a risk-adjusted basis, most would argue that a 7.12% government guarantee, reset to CPI-U every six months, with a floor of 0%, beats the average return over time of 8.57% with the possibility of a negative return on non-speculative savings for retirement.

Impact on Smallcap and Microcap Stocks

Amazon’s miss on earnings, Tesla’s 332 times P/E ratio, Facebook’s legal challenges, and the overall impact on tech of moving to the post-pandemic economy may not ever turn as negative as some might predict. However, the ability for conservative investors to earn a much higher rate than has been available for years exists now. While financial advisors acting as fiduciaries should make people aware of this, there is no financial incentive for them to. There are no commissions or fees to be made. The same for most media outlets that might be more prone to bring attention to their advertisers or discuss subjects more compelling than U.S. Savings Bonds. But the word will get out from sources like Channelchek and advocates for retirees such as AARP, AMAC, and astute bloggers.

If the large-cap index funds begin to see withdrawals, for the reasons mentioned above, risk-tolerant investors will seek two things. Better risk/return characteristics, and the “next FAANG” stock. This could cause them to look at stocks with much higher growth potential than a trillion-dollar company. The large-cap index trade has been easy and reliable over the past two years. But the landscape has definitely changed.

 

The chart above compares the last three months of performance of the Dow 30 (worst performer) the S&P 500, Nasdaq 100, and the Russell 2000 Small-Cap index (best performer). All have done historically well, but the smaller stocks are on a steeper trajectory upward. Investors looking for growth opportunities may be finding it harder to commit to large-cap stocks. Any money taken out of the markets by those now finding yields they require are invested in larger more established companies. This could set up the situation where smaller stocks outperform these larger ones going forward.

 

Take-Away

Underlying currents are what sets the long-term direction of financial markets. Over time, directions can become entrenched. Large-cap index funds became the alternative of choice to many highly conservative investors. The growth of the assets in these funds helped the upward direction that at least according to one well-followed hedge fund manager, has set up a possible disaster for these popular index funds.

As conservative investors revert back to their old ways, money could be moving out of S&P 500, Dow, and Nasdaq 100 funds. Those looking for the next FAANG stock, or as we like to say at Channelchek, “the next Apple” will look for growth industries and barely discovered gems. The data and research for registered users is here for those investors that know the current wave in index funds won’t last forever.

 

 Paul Hoffman

Managing Editor, Channelchek

Sources:

https://www.treasurydirect.gov/news/pressroom/currentibondratespr.htm

 

Stay up to date. Follow us:

 

QuickChek – November 8, 2021



Salem Media Group to Present at the Upcoming Q4 Investor Summit Conference

Salem Media Group announced it will present at the virtual Q4 Investor Summit conference at 1:00 P.M. Central Time on November 17, 2021

Research, News & Market Data on Salem Media

Watch recent presentation from Salem Media



PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute

PDS Biotechnology announced a licensing agreement with the National Cancer Institute

Research, News & Market Data on PDS Biotech

Watch recent presentation from PDS Biotech



Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses

Cocrystal Pharma announced that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral activity against human common coronaviruses, rhinoviruses, and respiratory enteroviruses that frequently cause the common cold, as well as against noroviruses that can cause symptoms of acute gastroenteritis

Research, News & Market Data on Cocrystal Pharma

Watch recent presentation from Cocrystal Pharma



Voyager Token Integrated Into Coinify’s Global Crypto Payment Platform

Voyager Digital announced the integration of the Voyager token (VGX) into Coinify’s cryptocurrency payment platform

Research, News & Market Data on Voyager Digital

Watch recent presentation from Voyager Digital

 

Stay up to date. Follow us:

 

Release – Salem Media Group to Present at the Upcoming Q4 Investor Summit Conference


Salem Media Group to Present at the Upcoming Q4 Investor Summit Conference

 

IRVING, Texas–(BUSINESS WIRE)– Salem Media Group, Inc. (NASDAQ: SALM) announced today it will present at the virtual Q4 Investor Summit conference at 1:00 P.M. Central Time on November 17, 2021. The presentation will be available on the investor relations portion of the company’s website www.salemmedia.com prior to the company’s presentation.

To request complimentary investor registration, please click here. To join the public Webcast, please click here.

ABOUT THE INVESTMENT SUMMIT:

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q4 Investor Summit will take place virtually, featuring 80+ companies and over 500 investors comprising of institutional investors, family offices, and high net worth investors.

ABOUT SALEM MEDIA GROUP:

Salem Media Group is America’s leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing. Each day Salem serves a loyal and dedicated audience of listeners and readers numbering in the millions nationally. With its unique programming focus, Salem provides compelling content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. Learn more about Salem Media Group, Inc. at www.salemmedia.comFacebook and Twitter.

Evan D. Masyr
Executive Vice President and Chief
Financial Officer
(805) 384-4512
evan@salemmedia.com

Source: Salem Media Group, Inc.

Released November 8, 2021

Release – PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia Prostate and Breast Cancers from National Cancer Institute


PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute

 

Advances Next Phase of Versamune® Oncology Pipeline

FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced a licensing agreement with the National Cancer Institute (NCI) for intellectual property related to the NCI’s proprietary tumor-associated and immunologically active T-cell receptor gamma alternate reading frame protein (TARP).

Approximately 470,000 patients are diagnosed annually with TARP-associated cancers, including acute myeloid leukemia (AML), prostate, and breast cancer according to the National Cancer Institute. In preclinical studies performed by PDS Biotech, the administration of PDS0102, the Versamune®-TARP tumor antigen combination, led to the induction of large numbers of tumor targeted killer T-cells. It is important to note, the TARP tumor antigen alone has already been studied at the NCI in men with prostate cancer and been shown to be safe, immunogenic, and associated with slowing tumor growth rates (NCT00972309).
  
“The highly promising proof-of-concept data presented earlier this year in the advanced HPV cancer trial solidifies our confidence in the Versamune® technology to rapidly advance our pipeline into other types of debilitating cancers,” said Dr. Lauren V. Wood, PDS Biotech’s Chief Medical Officer. “We are excited about the potential of PDS0102, which leverages the Versamune® platform to improve on the results reported in humans with the NCI’s TARP antigen alone.”

The worldwide, non-exclusive license secures rights for the proprietary TARP antigen from the NCI with patent protection through 2034.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Company’s proprietary Versamune® T-cell activating technology platform. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including breast, colon, lung, prostate and ovarian cancers.   To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0102

PDS0102 combines the utility of the Versamune® platform with the proprietary T-cell receptor gamma alternate reading frame protein (TARP), a tumor antigen identified by the National Cancer Institute (NCI) which is strongly associated with acute myeloid leukemia (AML), breast and prostate cancers. Approximately 470,000 patients are projected to be diagnosed with AML, prostate, or breast cancer this year, most of which are associated with TARP.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® based products; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® based products and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: 
mailto:drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: mailto:rich@cg.capital

Release – Voyager Token Integrated Into Coinifys Global Crypto Payment Platform

 


Voyager Token Integrated Into Coinify’s Global Crypto Payment Platform

 

Integration increases VGX functionality as customers can utilize it for crypto payments

NEW YORKNov. 8, 2021 /PRNewswire/ – Voyager Digital Ltd. (“Voyager” or the “Company”) (TSX: VOYG) (OTCQX: VYGVF) (FRA: UCD2), one of the fastest-growing, publicly traded cryptocurrency platforms in the United States, today announced the integration of the Voyager token (VGX) into Coinify’s cryptocurrency payment platform, a wholly-owned Voyager subsidiary that provides merchant payment services in over 150 countries.

“The integration of VGX into Coinify’s crypto payment platform expands the functionality of the Voyager token well beyond the Voyager ecosystem,” said Steve Ehrlich, CEO and Co-founder of Voyager. “Our acquisition of Coinify earlier this year added a global crypto payments infrastructure to the Voyager ecosystem, and we will continue to implement additional ways to maximize this infrastructure to grow crypto adoption internationally.”

Coinify’s payment system allows businesses to accept cryptocurrency online and in retail stores, and is integrated through payment service providers with over 30,000 merchants globally. VGX joins over 15 other leading cryptocurrencies — including Bitcoin, Ethereum, and Cardano — that can be accepted by participating Coinify merchants. Voyager also previously announced that Usio, its payment provider, is integrating Coinify’s payment offering. Usio already has an established pipeline of merchants and PSPs ready to accept crypto as payment.

VGX supports the Voyager Loyalty Program, commonly known as VLP, which allows customers to earn rewards for activities done on the platform. The VLP rewards customers with crypto-back on trades, boosted holding rewards, and more. The program has been successful as the number of participants continues to grow.

In August 2021, Voyager acquired Coinify, accelerating Voyager’s international expansion and the Company’s payment capabilities, with plans to enable customers to make payments directly from their digital asset accounts and fast-track Voyager into the business-to-business payment space.

About Voyager Digital Ltd.
Voyager Digital Ltd. (TSX: VOYG;OTCQX: 
VYGVF; FRA: UCD2) is a fast-growing, publicly traded cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost efficiency to the marketplace. Voyager offers a secure way to trade over 60 different crypto assets using its easy-to-use mobile application, and earn rewards up to 12 percent annually on more than 30 cryptocurrencies. Through its subsidiary Coinify ApS, Voyager provides crypto payment solutions for both consumers and merchants around the globe. To learn more about the company, please visit https://www.investvoyager.com.

The TSX has not approved or disapproved of the information contained herein.

Press Contacts:

Voyager Digital, Ltd.
Michael Legg
Chief Communications Officer
(212) 547-8807
mailto:mlegg@investvoyager.com


Voyager Public Relations Team
mailto:pr@investvoyager.com

SOURCE Voyager Digital (Canada) Ltd.

Release – Cocrystal Pharmas SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity


Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses

 

BOTHELL, Wash., Nov. 08, 2021 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral activity against human common coronaviruses, rhinoviruses, and respiratory enteroviruses that frequently cause the common cold, as well as against noroviruses that can cause symptoms of acute gastroenteritis. These protease inhibitors were discovered using the company’s proprietary structure-based drug discovery technology and are currently being advanced by Cocrystal toward clinical development to combat SARS-CoV-2 and its variants.

“It is exciting and compelling to see the pan-viral activity of our SARS-CoV-2 main protease inhibitors against these clinically important viruses that cause illness among millions of people worldwide each year,” said Sam Lee, Ph.D., Cocrystal’s President and interim co-CEO. “As we have observed the importance of repurposed broad-spectrum antiviral drugs during the COVID-19 pandemic, it is extremely important to design and rapidly develop new drug candidates as potent and safe pan-antivirals. This could be a gamechanger for antiviral drug discovery paradigms and treatments.

“Our current focus is on advancing these SARS-CoV-2 main protease inhibitors toward clinical development as a potential oral treatment for patients with COVID-19,” he added. “We now have additional opportunities with these same protease inhibitors for future programs that target other areas of high unmet medical need.”

About Human Common Coronaviruses
Common human coronaviruses, not to be confused with SARS-CoV-2, usually cause mild to moderate upper-respiratory tract illnesses, like the common cold. Most people become infected with one or more of these viruses at some point in their lives. In the U.S., people usually become infected with common human coronaviruses in the fall and winter although these people can become infected any time of the year. Young children are most likely to get infected and people can have multiple infections in their lifetime. For further information, please visit: https://www.cdc.gov/coronavirus/types.html

About Human Rhinoviruses and Respiratory Enteroviruses
Human rhinoviruses are responsible for more than one-half of cold-like illnesses and cost billions of dollars annually in direct medical care and missed days of work. Along with respiratory enteroviruses, rhinoviruses are the leading cause of upper respiratory tract infections and are among the most frequent infectious agents that affect humans worldwide. However, the lack of efficient antiviral treatments or vaccines against these highly prevalent and contagious pathogens prevents effective management of related diseases. For more information, please visit: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728576/

About Human Noroviruses
Noroviruses are global public health problem and the leading cause of vomiting and diarrhea from acute gastroenteritis among people of all ages in the U.S. and a Noroviruses are notorious for their common occurrence in hospitals, nursing homes, childcare facilities, schools, and cruise ships. In the U.S. alone, the Centers for Diseases Control and Prevention (CDC) estimates that noroviruses to cause up to 21 million illnesses, contribute to more than 100,000 hospitalizations and 900 deaths, and are responsible for nearly 1 million pediatric medical care visits annually. For more information, please visit: https://www.cdc.gov/norovirus/trends-outbreaks/burden-US.html

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2), influenza viruses, hepatitis C virus, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential of the company’s main protease inhibitors as a COVID-19 oral treatment and the potential to treat other viruses. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from the delays in furthering research due to the supply chain impact including manufacturing and research delays arising from raw material and test animal shortages and other supply chain disruptions, potential delays related to the FDA’s review of our submissions, receipt of regulatory approvals, the results of any future clinical trials, general risks arising from clinical trials, regulatory changes, and development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Source: Cocrystal Pharma, Inc.

Ocugen (OCGN) – Covaxin Pediatric Application Filed Listed for Emergency Use

Monday, November 08, 2021

Ocugen (OCGN)
Covaxin Pediatric Application Filed, Listed for Emergency Use

Ocugen Inc is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Emergency Pediatric Use Application Filed. Ocugen announced that it has filed an Emergency Pediatric Use application for Covaxin in children from age 2 to 18 year of age. The data for the application was from the Phase 2/3 study conducted by Bharat Biotech that included 529 children in its total enrollment of 25,800 patients. Separately, the World Health Organization (WHO) has issued an Emergency Use Listing for Covaxin.

    WHO Listing Followed Clinical Data Assessment.  Covaxin was reviewed by the WHO’s Strategic Advisory Group of Experts on immunization (SAGE), the advisory group that makes WHO vaccination policy. SAGE evaluated the Phase 2 and Phase 3 clinical data for safety and efficacy. It determined that Covaxin meets WHO standards and endorsed its use for vaccination programs worldwide …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Information Services (III) – Post Call Commentary Raising PT

Monday, November 08, 2021

Information Services (III)
Post Call Commentary; Raising PT

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 clients, including more than 70 of the top 100 enterprises in the world, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    All Things Digital. ISG’s portfolio of products and services built around all things digital is in high demand, and the success is being amplified by ISG’s NEXT operating model. This was the fifth consecutive quarter of outstanding results coming out of the pandemic.

    ISG NEXT.  The Company’s ISG NEXT operating model is generating significant operating improvement. For example, SG&A expenses fell to 27.1% of revenues in the qtr., down from 33.0% last year. Adjusted EBITDA margin grew to 14.4% from 13.3% last year …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Helius Medical Technologies (HSDT)(HSM:CA) – PoNS Market Authorization in Australia

Monday, November 08, 2021

Helius Medical Technologies (HSDT)(HSM:CA)
PoNS Market Authorization in Australia

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Gregory Aurand, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Australia Approval. Late last week, Helius announced it had received authorization from the Australian Therapeutic Goods Administration (TGA) for the sale of PoNS as a Class IIa (low-to-medium risk) medical device. Notably the authorization is for all indications, opening a much bigger market opportunity for the Company. In fact, the Australian market could be larger than the more populous Canadian market due to the Australian authorization.

    Next Steps.  Helius is working with the TGA to finalize the exact scope of the authorization, which is expected to cover the use of PoNS to improve balance and gait when used as an adjunct to a therapeutic exercise program. Helius will begin evaluating the pathway toward commercialization in Australia once the scope of the authorization is finalized …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

E.W. Scripps (SSP) – We Are Connected

Monday, November 08, 2021

E.W. Scripps (SSP)
We Are Connected!

The E.W. Scripps Co. (www.scripps.com) serves audiences and businesses through a growing portfolio of television, print and digital media brands. After approval of its acquisition of two Granite Broadcasting stations later this year, Scripps will own 21 local television stations as well as daily newspapers in 13 markets across the United States. It also runs an expanding collection of local and national digital journalism and information businesses including digital video news service Newsy. Scripps also produces television programming, runs an award-winning investigative reporting newsroom in Washington, D.C., and serves as the longtime steward of one of the nation’s largest, most successful and longest-running educational programs, Scripps National Spelling Bee. Founded in 1879, Scripps is focused on the stories of tomorrow.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Q3 exceeds expectations. Total company revenues increased 11.7% to $555.2 million, which was slightly above our $546.8 million estimate. The largest upside revenue variance was in the company’s Networks segment, which increased 17.8%, above our 14.2% growth estimate and above management’s previous guidance of up mid teens. Adjusted EBITDA was $132.4 million, 14.3% above our $115.8 million estimate. The largest EBITDA variance was in its Network segment. Our original estimates factored in higher costs due to the launch of Newsy, Defy and True—-.

    Limited supply chain/labor shortage impact.  All of its leading advertising categories are trending favorably and more than offsetting the Auto category, which has been hurt by chip shortages. Management indicated that Auto may not rebound until the second half 2022. Nonetheless, all other categories are growing nicely, including a large emerging ad category, Sports Betting …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.